Ozempic and Wegovy contain semaglutide, while Mounjaro contains tirzepatide. These medicines work by affecting appetite, slowing stomach emptying, and helping people feel fuller for longer. Ozempic is authorised in the EU for type 2 diabetes, Wegovy is authorised for weight management, and Mounjaro is authorised for both type 2 diabetes and weight management in appropriate patients.

The most commonly reported side effects with these medicines are gastrointestinal, especially nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. Side effects are often more noticeable when starting treatment or increasing the dose, which is why dose escalation is usually gradual.

Results vary from person to person. Weight loss is usually gradual and tends to improve when treatment is combined with dietary changes, physical activity, and regular follow-up. These medicines are intended to be used alongside lifestyle measures rather than as a replacement for them.

These medicines are regulated prescription treatments, but suitability depends on the individual patient, their medical history, current medicines, and treatment goal. They should only be used under appropriate professional supervision, and patients should follow the product instructions and prescribing advice carefully.

The best first step is to speak with a pharmacist or prescriber for an assessment. They can review your goals, medical history, current treatment, and whether a medicine such as Ozempic, Mounjaro, or Wegovy may be appropriate for you. Because these medicines have different authorised uses in Europe, the right option depends on your clinical situation.